Madrigal Pharmaceuticals Receives Three Resmetirom Patents From U.S. Patent And Trademark Office
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. MDGL | 0.00 |
- New U.S. Rezdiffra patents in F2/F3 to be listed in FDA’s Orange Book
- U.S. Patent No. 12,667,575, directed to administering a weight-threshold step-down 60mg or 80mg resmetirom dose for patients with F2/F3 MASH also using a moderate CYP2C8 inhibitor. This patent issued on June 30, 2026, and is expected to provide protection to 2045.
- U.S. Patent No. 12,661,359, directed to the administration of rosuvastatin and resmetirom and limits the daily dose of rosuvastatin to a maximum of 20mg per day to reduce or eliminate dose-related side effects. This patent issued on June 23, 2026, and is expected to provide protection to 2042.
- New U.S. resmetirom patent in F4c
- U.S. Patent No. 12,661,361, directed to a method of administering resmetirom to treat well-compensated cirrhosis (F4c). This patent issued on June 23, 2026, and is expected to provide protection to 2042.